Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Pitt B"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 38
Tytuł:
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Autorzy:
Ferreira JP; Cardiovascular R&D Centre - , Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine of the University of Porto, Porto, Portugal.; Internal Medicine Departament, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique, 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
Cleland JG; Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
Girerd N; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique, 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
Bozec E; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique, 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
Rossignol P; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique, 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
Pellicori P; Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
Cosmi F; Department of Cardiology, Cortona Hospital, Arezzo, Italy.
Mariottoni B; Department of Cardiology, Cortona Hospital, Arezzo, Italy.
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pitt B; Division of Cardiology, University of Michigan, Ann Arbor, MI, USA.
Pfeffer MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Shah AM; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Petutschnigg J; Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin, Germany & German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Pieske B; Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin, Germany & German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Edelmann F; Division of Cardiology, University of Michigan, Ann Arbor, MI, USA.
Zannad F; Internal Medicine Departament, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2023 Jan; Vol. 25 (1), pp. 108-113. Date of Electronic Publication: 2022 Nov 09.
Typ publikacji:
Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Spironolactone*/therapeutic use
Heart Failure*/diagnostic imaging
Heart Failure*/drug therapy
Heart Failure*/epidemiology
Humans ; Female ; Aged ; Male ; Stroke Volume ; Mineralocorticoid Receptor Antagonists ; Ventricular Function, Left ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Application of the H 2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.
Autorzy:
Myhre PL; Brigham and Women's Hospital, Boston, MA, USA.; Akershus University Hospital and University of Oslo, Oslo, Norway.
Vaduganathan M; Brigham and Women's Hospital, Boston, MA, USA.
Claggett BL; Brigham and Women's Hospital, Boston, MA, USA.
Lam CSP; National Heart Centre Singapore, Duke-National University of Singapore, Singapore.
Desai AS; Brigham and Women's Hospital, Boston, MA, USA.
Anand IS; VA Medical Center, University of Minnesota, Minneapolis, MN, USA.
Sweitzer NK; University of Arizona, Tucson, AZ, USA.
Fang JC; University of Utah, Salt Lake City, UT, USA.
O'Meara E; Montreal Heart Institute, University of Montreal, Montreal, QC, Canada.
Shah SJ; Northwestern University, Chicago, IL, USA.
Shah AM; Brigham and Women's Hospital, Boston, MA, USA.
Lewis EF; Brigham and Women's Hospital, Boston, MA, USA.
Rouleau J; Montreal Heart Institute, University of Montreal, Montreal, QC, Canada.
Pitt B; University of Michigan School of Medicine, Ann Arbor, MI, USA.
Solomon SD; Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2019 Oct; Vol. 21 (10), pp. 1288-1291. Date of Electronic Publication: 2019 Jul 22.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural
MeSH Terms:
Heart Failure/*drug therapy
Heart Failure/*physiopathology
Mineralocorticoid Receptor Antagonists/*therapeutic use
Spironolactone/*therapeutic use
Aged ; Double-Blind Method ; Female ; Humans ; Internationality ; Male ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Stroke Volume
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
Autorzy:
Selvaraj S; Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Claggett B; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Shah SJ; Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Anand I; VA Medical Center and University of Minnesota, Minneapolis, MN, USA.
Rouleau JL; Department of Medicine, Montreal Heart Institute, University of Montreal, Quebec, Canada.
Desai AS; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Lewis EF; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pitt B; University of Michigan, Ann Arbor, MI, USA.
Sweitzer NK; Sarver Heart Center, University of Arizona College of Medicine, Tucson, USA.
Pfeffer MA; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Solomon SD; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2018 Mar; Vol. 20 (3), pp. 483-490. Date of Electronic Publication: 2017 Nov 16.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms:
Blood Pressure/*drug effects
Heart Failure/*drug therapy
Spironolactone/*administration & dosage
Stroke Volume/*physiology
Aged ; Blood Pressure/physiology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Follow-Up Studies ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Mineralocorticoid Receptor Antagonists/administration & dosage ; Retrospective Studies ; Systole ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Autorzy:
Olivier A; Inserm CIC Plurithématique 1433, UMRS 1116 Inserm, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; Cardiovascular Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; F-CRIN INI-CRCT, France.
Pitt B; University of Michigan, School of Medicine, Ann Arbor, MI, USA.
Girerd N; Inserm CIC Plurithématique 1433, UMRS 1116 Inserm, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; F-CRIN INI-CRCT, France.; Université de Lorraine, Nancy, France.; Fédération de Recherche 3209, Vandoeuvre-lès-Nancy, France.
Lamiral Z; Inserm CIC Plurithématique 1433, UMRS 1116 Inserm, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; F-CRIN INI-CRCT, France.
Machu JL; Inserm CIC Plurithématique 1433, UMRS 1116 Inserm, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; F-CRIN INI-CRCT, France.
McMurray JJV; University of Glasgow, Glasgow, UK.
Swedberg K; University of Gothenburg, Gothenburg, Sweden.
van Veldhuisen DJ; University Medical Center, Groningen, the Netherlands.
Collier TJ; London School of Hygiene and Tropical Medicine, London, UK.
Pocock SJ; London School of Hygiene and Tropical Medicine, London, UK.
Rossignol P; Inserm CIC Plurithématique 1433, UMRS 1116 Inserm, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; F-CRIN INI-CRCT, France.; Université de Lorraine, Nancy, France.; Fédération de Recherche 3209, Vandoeuvre-lès-Nancy, France.
Zannad F; Inserm CIC Plurithématique 1433, UMRS 1116 Inserm, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; Cardiovascular Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; F-CRIN INI-CRCT, France.; Université de Lorraine, Nancy, France.; Fédération de Recherche 3209, Vandoeuvre-lès-Nancy, France.
Pizard A; Inserm CIC Plurithématique 1433, UMRS 1116 Inserm, CHRU Nancy, Vandoeuvre-lès-Nancy, France.; F-CRIN INI-CRCT, France.; Université de Lorraine, Nancy, France.; Fédération de Recherche 3209, Vandoeuvre-lès-Nancy, France.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2017 Sep; Vol. 19 (9), pp. 1186-1197. Date of Electronic Publication: 2017 Mar 16.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Heart Failure, Systolic*/complications
Heart Failure, Systolic*/diagnosis
Heart Failure, Systolic*/drug therapy
Heart Failure, Systolic*/metabolism
Obesity, Abdominal*/complications
Obesity, Abdominal*/diagnosis
Obesity, Abdominal*/metabolism
Ventricular Dysfunction, Left*/diagnosis
Ventricular Dysfunction, Left*/metabolism
Ventricular Dysfunction, Left*/mortality
Spironolactone/*analogs & derivatives
Aged ; Aldosterone/metabolism ; Drug Monitoring/methods ; Eplerenone ; Female ; Humans ; Male ; Middle Aged ; Mineralocorticoid Receptor Antagonists/administration & dosage ; Mineralocorticoid Receptor Antagonists/adverse effects ; Spironolactone/administration & dosage ; Spironolactone/adverse effects ; Stroke Volume ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
Autorzy:
Rossignol P; Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, Nancy, France.; CHU Nancy, Pôle de Cardiologie, Vandoeuvre lès Nancy, France.; Université de Lorraine, France.; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Girerd N; Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, Nancy, France.; CHU Nancy, Pôle de Cardiologie, Vandoeuvre lès Nancy, France.; Université de Lorraine, France.; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Bakris G; ASH Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL, USA.
Vardeny O; University of Wisconsin School of Pharmacy, Madison, WI, USA.
Claggett B; Brigham and Women's Hospital, Boston, MA, USA.
McMurray JJV; The British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Swedberg K; Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Krum H; Monash University, Melbourne, VIC, Australia.
van Veldhuisen DJ; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Shi H; Pfizer, NY, USA.
Spanyers S; Pfizer, NY, USA.
Vincent J; Pfizer, NY, USA.
Fay R; Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, Nancy, France.; CHU Nancy, Pôle de Cardiologie, Vandoeuvre lès Nancy, France.; Université de Lorraine, France.; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Lamiral Z; Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, Nancy, France.; CHU Nancy, Pôle de Cardiologie, Vandoeuvre lès Nancy, France.; Université de Lorraine, France.; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Solomon SD; Brigham and Women's Hospital, Boston, MA, USA.
Zannad F; Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, Nancy, France.; CHU Nancy, Pôle de Cardiologie, Vandoeuvre lès Nancy, France.; Université de Lorraine, France.; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Pitt B; University of Michigan School of Medicine, Ann Arbor, MI, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2017 Jun; Vol. 19 (6), pp. 792-799. Date of Electronic Publication: 2016 Nov 20.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Heart Failure, Systolic/*drug therapy
Hypokalemia/*etiology
Spironolactone/*analogs & derivatives
Dose-Response Relationship, Drug ; Eplerenone ; Europe/epidemiology ; Female ; Follow-Up Studies ; Heart Failure, Systolic/mortality ; Heart Failure, Systolic/physiopathology ; Humans ; Hypokalemia/blood ; Hypokalemia/drug therapy ; Male ; Mineralocorticoid Receptor Antagonists/administration & dosage ; Prognosis ; Spironolactone/administration & dosage ; Survival Rate/trends ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Autorzy:
Chin KL; Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.
Collier TJ; London School of Hygiene and Tropical Medicine, London, UK.
Pitt B; University of Michigan School of Medicine, Ann Arbor, MI, USA.
McMurray JJ; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.; National Heart and Lung Institute, Imperial College, London, UK.
van Veldhuisen DJ; University of Groningen, Groningen, The Netherlands.
Pocock SJ; London School of Hygiene and Tropical Medicine, London, UK.
Vincent J; Pfizer, New York, USA.
Turgonyi E; Pfizer, New York, USA.
Zannad F; CHU and University Henri Poincaré, Nancy, France.
Krum H; Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.
Pokaż więcej
Corporate Authors:
EMPHASIS-HF Study Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2016 Sep; Vol. 18 (9), pp. 1175-81. Date of Electronic Publication: 2016 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Aspirin/*therapeutic use
Heart Failure, Systolic/*drug therapy
Mineralocorticoid Receptor Antagonists/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Spironolactone/*analogs & derivatives
Aged ; Blood Pressure ; Chronic Disease ; Drug Interactions ; Eplerenone ; Female ; Glomerular Filtration Rate ; Heart Failure, Systolic/physiopathology ; Humans ; Male ; Potassium/blood ; Proportional Hazards Models ; Spironolactone/therapeutic use ; Stroke Volume
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Autorzy:
Cannon JA; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Collier TJ; London School of Hygiene & Tropical Medicine, London, UK.
Shen L; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Swedberg K; University of Gothenburg, Gothenburg, Sweden.
Krum H; Monash University, Melbourne, Australia.
Van Veldhuisen DJ; University Medical Centre Groningen, The Netherlands.
Vincent J; Pfizer Pharma, NY, USA.
Pocock SJ; London School of Hygiene & Tropical Medicine, London, UK.
Pitt B; University of Michigan, MI, USA.
Zannad F; Nancy Université, Nancy, France Inserm, Université de Lorraine and CHU de Nancy, Nancy, France.
McMurray JJ; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Jul; Vol. 17 (7), pp. 707-16.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Electrocardiography*
Heart Failure/*drug therapy
Hospitalization/*statistics & numerical data
Mineralocorticoid Receptor Antagonists/*therapeutic use
Spironolactone/*analogs & derivatives
Aged ; Double-Blind Method ; Eplerenone ; Female ; Heart Failure/mortality ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Random Allocation ; Spironolactone/therapeutic use ; Stroke Volume/physiology ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Autorzy:
Pitt B; University of Michigan Medical School, 1500 E Medical Center Drive, 3910 Tauman Ctr, Ann Arbor, MI, 48109 0366, USA.
Anker SD
Böhm M
Gheorghiade M
Køber L
Krum H
Maggioni AP
Ponikowski P
Voors AA
Zannad F
Nowack C
Kim SY
Pieper A
Kimmeskamp-Kirschbaum N
Filippatos G
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2015 Feb; Vol. 17 (2), pp. 224-32.
Typ publikacji:
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetes Mellitus, Type 2/*drug therapy
Heart Failure/*drug therapy
Mineralocorticoid Receptor Antagonists/*therapeutic use
Naphthyridines/*therapeutic use
Renal Insufficiency, Chronic/*drug therapy
Spironolactone/*analogs & derivatives
Comorbidity ; Diabetes Mellitus, Type 2/blood ; Double-Blind Method ; Eplerenone ; Heart Failure/blood ; Humans ; Mineralocorticoid Receptor Antagonists/adverse effects ; Naphthyridines/adverse effects ; Natriuretic Agents/blood ; Natriuretic Peptide, Brain/blood ; Peptide Fragments/blood ; Renal Insufficiency, Chronic/blood ; Spironolactone/adverse effects ; Spironolactone/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
Autorzy:
Iqbal J; Department of Cardiovascular Science at the University of Sheffield, and Cardiology Department at Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Fay R
Adlam D
Squire I
Parviz Y
Gunn J
Pitt B
Zannad F
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2014 Jun; Vol. 16 (6), pp. 685-91. Date of Electronic Publication: 2014 Apr 04.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Percutaneous Coronary Intervention*
Mineralocorticoid Receptor Antagonists/*therapeutic use
Myocardial Infarction/*drug therapy
Spironolactone/*analogs & derivatives
Ventricular Dysfunction, Left/*drug therapy
Aged ; Aged, 80 and over ; Comorbidity ; Double-Blind Method ; Eplerenone ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction/surgery ; Spironolactone/therapeutic use ; Treatment Outcome ; Ventricular Dysfunction, Left/mortality
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Autorzy:
Iqbal J; Department of Cardiovascular Science at the University of Sheffield and Cardiology Department at Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Parviz Y
Pitt B
Newell-Price J
Al-Mohammad A
Zannad F
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2014 Feb; Vol. 16 (2), pp. 143-50. Date of Electronic Publication: 2013 Dec 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Heart Failure/*drug therapy
Hypertension/*drug therapy
Mineralocorticoid Receptor Antagonists/*therapeutic use
Spironolactone/*analogs & derivatives
Spironolactone/*therapeutic use
Ventricular Dysfunction, Left/*drug therapy
Eplerenone ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial.
Autorzy:
Dobre D; INSERM, Center of Clinical Investigation 9501, Lorraine Institute of Heart and Vessels Louis Mathieu, University Hospital Nancy, France. />Rossignol P
Murin J
Parkhomenko A
Lamiral Z
Krum H
van Veldhuisen DJ
Pitt B
Zannad F
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2013 Feb; Vol. 15 (2), pp. 221-7. Date of Electronic Publication: 2012 Aug 07.
Typ publikacji:
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Heart Failure, Systolic/*drug therapy
Heart Failure, Systolic/*mortality
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Mineralocorticoid Receptor Antagonists/*therapeutic use
Myocardial Infarction/*drug therapy
Myocardial Infarction/*mortality
Spironolactone/*analogs & derivatives
Acute Disease ; Aged ; Double-Blind Method ; Drug Therapy, Combination ; Eplerenone ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Male ; Middle Aged ; Mineralocorticoid Receptor Antagonists/adverse effects ; Propensity Score ; Spironolactone/adverse effects ; Spironolactone/therapeutic use ; Stroke Volume/drug effects ; Survival Analysis ; Treatment Outcome ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
Autorzy:
Adamopoulos C; Inserm, Centre d'Investigations Cliniques CIC Inserm CHU and U961, Hôpital Jeanne d' Arc, Toul 54200, France.
Ahmed A
Fay R
Angioi M
Filippatos G
Vincent J
Pitt B
Zannad F
Pokaż więcej
Corporate Authors:
EPHESUS Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2009 Nov; Vol. 11 (11), pp. 1099-105.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure/*drug therapy
Mineralocorticoid Receptor Antagonists/*administration & dosage
Myocardial Infarction/*drug therapy
Spironolactone/*analogs & derivatives
Ventricular Dysfunction, Left/*drug therapy
Death, Sudden, Cardiac/prevention & control ; Double-Blind Method ; Eplerenone ; Female ; Heart Failure/etiology ; Heart Failure/mortality ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Myocardial Infarction/complications ; Myocardial Infarction/mortality ; Proportional Hazards Models ; Risk Factors ; Spironolactone/administration & dosage ; Spironolactone/therapeutic use ; Survival Rate ; Time Factors ; Treatment Outcome ; Ventricular Dysfunction, Left/etiology ; Ventricular Dysfunction, Left/mortality
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
Autorzy:
Pitt B; University of Michigan Medical Center, Alfred Taubman Health Care Center, 1500 East Medical Center Drive, Ann Arbor, 48109, USA. />Gheorghiade M
Zannad F
Anderson JL
van Veldhuisen DJ
Parkhomenko A
Corbalan R
Klug EQ
Mukherjee R
Solomon H
Pokaż więcej
Corporate Authors:
EPHESUS Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2006 May; Vol. 8 (3), pp. 295-301. Date of Electronic Publication: 2006 Feb 28.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Heart Failure/*drug therapy
Myocardial Infarction/*complications
Spironolactone/*analogs & derivatives
Stroke Volume/*drug effects
Ventricular Function, Left/*drug effects
Adult ; Aged ; Eplerenone ; Female ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Spironolactone/adverse effects ; Spironolactone/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 38

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies